Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.60 |
| ▸ | BRD2 | P25440 | 1/20 | 0.60 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.60 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | CNR2 | P34972 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1137191 | 0.92 | BRD4 (0.70) | BRD4BRD2BRD3BRDTMAPT | |
| SCHEMBL4983592 | 0.90 | BRD4 (0.67) | BRD4BRD2BRD3BRDTMAPT | |
| SCHEMBL4997385 | 0.89 | MAPT (0.61) | BRD4BRD2BRD3BRDTMAPT | |
| SCHEMBL4817512 | 0.86 | CNR1 (0.59) | BRD4BRD2BRD3BRDTMAPT | |
| SCHEMBL4429575 | 0.85 | KDM4E (0.55) | BRD4BRD2BRD3BRDTMAPT | |
| SCHEMBL4993019 | 0.85 | BRD4 (0.59) | BRD4BRD2BRD3BRDTMAPT | |
| SCHEMBL4995076 | 0.83 | KDM4E (0.56) | BRD4BRD2BRD3BRDTMAPT | |
| SCHEMBL4438770 | 0.82 | MAPT (0.53) | BRD4BRD2BRD3BRDTMAPT | |
| SCHEMBL4425995 | 0.82 | MAPT (0.56) | BRD4BRD2BRD3BRDTMAPT | |
| SCHEMBL28383670 | 0.82 | BRD4 (0.56) | BRD4BRD2BRD3BRDTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | BRD4 2776/4885BRD2 4008/4885BRD3 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.